Health News Releases

  • Today September 22
July 27, 10:00
AmbioPharm, a Global Peptide CDMO
AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production. A reliable peptide CDMO with manufacturing faci
July 26, 17:35
Aleph Farms Submits First Ever Application for Cultivated Meat in Europe
Aleph Farms, a cellular agriculture company that enhances sustainability, food security and animal welfare in our food systems, today announced that it has submitted an application for regulatory appr
July 26, 17:15
BaroPace Receives Approval for First-in-Human Clinical Trial
BaroPace, Inc., a medical technology company dedicated to using blood pressure to regulate pacemakers for patients with heart failure with preserved ejection fraction and hypertension, announced today
July 26, 10:45
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),[8] Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced
July 25, 11:30
Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johns
July 25, 11:15
Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus
Orthogon Therapeutics LLC, a trailblazer in the field of antiviral therapeutics, today announced a dual victory. Orthogon’s lead molecule has successfully completed acute toxicity studies, marking a p
July 21, 11:45
Kenvue Initiates Quarterly Cash Dividend
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the third quarter
July 17, 09:30
TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), today announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impa
(Photo: Wyss Center for Bio and Neuroengineering)
July 11, 10:05
Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing
The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appoi
July 07, 09:10
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agree
Gachon University Gil Medical Center (Gil Medical Center), a pioneering health provider with many “f
July 06, 13:08
Rimini Support™ Enables Gachon University Gil Medical Center to Advance its Digital Transformation Projects and Continue to Serve the Community as a Trailblazer Hospital
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Sale
July 06, 10:15
First Distribution Agreement Executed with Sonic Healthcare
Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Dougl
GilletteLabs Razor with Exfoliating Bar (Photo: Business Wire)
July 05, 09:30
P&G Grooming Invites Dermatologist Community to Go ‘Skin Deep Into Grooming’ at the 25th World Congress of Dermatology
At this year’s 25th World Congress of Dermatology held in Singapore (July 3rd - 8th), P&G’s Grooming Division will spotlight product solutions routed in 120 years of innovation heritage and scientific
July 04, 17:11
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4
Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of action of nemolizum
About Generalized Pustular Psoriasis (Graphic: Business Wire)
July 04, 16:25
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Today, at the 25th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab significantly reduced the risk of GPP
Audience at IMPAHCT (International Meeting on Pulmonary Hypertension Clinical Treatment) organized b
July 04, 10:10
Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers
The IMPAHCT (International Meeting on Pulmonary Hypertension Clinical Treatment) event, organized by the pharmaceutical company Ferrer, has brought together more than 150 pulmonologists and cardiologi
July 04, 09:50
After the Great Success Achieved in the United States and Canada, DEKA Launches Three Extraordinary Laser and Microwave Platforms at the World Congress of Dermatology in Singapore
DEKA, a subsidiary of the El.En. Group, a company listed on the Eurostar Next of the Italian Stock Exchange (ELN.MI), specialized in the development and manufacturing of cutting-edge Energy Based Devi
OncoPro Tumoroid Culture Medium Kit (Photo: Business Wire)
June 29, 14:05
Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifica
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climat
June 29, 11:40
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative coli
June 29, 09:55
Microba Commences Phase I Clinical Trial for IBD Therapeutic
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) today announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Th
Aktana welcomes John Vitalie as Chief Executive Officer (Photo: Business Wire)
June 29, 09:15
Aktana Announces New CEO
Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes John Vitalie as Chief Executive Officer. Before joining Aktana, John led global teams across va
June 28, 16:22
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology
Galderma will be presenting 59 abstracts/posters from across its extensive portfolio at the 25th World Congress of Dermatology (WCD), reflecting its unrelenting dedication to delivering innovative sol
June 28, 10:20
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report. The report highlights the company’s progres
June 27, 10:15
Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round
Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholder
June 27, 09:55
Vertex Ventures HC Announces $200 Million Fund III to Drive Innovation in Healthcare
Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 million. Fund III will be deployed to support and empo
June 26, 09:00
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (r
June 25, 13:26
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with over
Lab work
June 25, 13:20
Artilysin® - A Groundbreaking “Green Pharma” Solution
Lysando, the leading pioneer in the field of antimicrobial proteins has achieved significant milestones with its cutting-edge Artilysin® technology. This innovative platform has demonstrated a distinc
June 25, 10:56
Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with
Matthew-Shippey-Joins-IPS-as-Managing-Director-APAC (Photo: Business Wire)
June 25, 10:32
IPS Strengthens Asia and Pacific Presence with New Managing Director, Matthew Shippey
IPS, a leading provider of architecture, engineering, procurement, construction management, and validation services, announces the appointment of an industry-leading professional, Matthew Shippey, to
Brainlab, the AO Foundation and Level Ex sign an agreement at the AO Trustees Meeting, June 22 in Sy
June 23, 11:15
Brainlab and the AO Foundation Collaborate on the Future of Immersive Medical Education and Training
Brainlab, a digital medical technology company, announced today an expanded collaboration outlining initiatives in their ongoing work with the AO Foundation. Signed at the annual AO Trustees Meeting—h
Masimo W1™ and Hospital La Fe, Valencia, Spain (Photo: Business Wire)
June 23, 10:41
Hospital La Fe Expands Telehealth Program with Masimo W1™ for Preoperative Patients
Masimo (NASDAQ: MASI) today announced that Hospital La Fe in Valencia, Spain, is expanding its telehealth and telemonitoring program with the Masimo W1™ advanced health tracking watch. Masimo W1, whic
June 22, 14:25
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovati
(Photo: Business Wire)
June 22, 10:55
Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)
The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122 in amyotrophic lateral sclerosis (A
June 21, 11:30
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyalur
June 18, 14:00
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previous
June 16, 15:55
SciMed (Asia), Life Science Sales and Service Distributing Subsidiary of PHC Holdings Corporation, Becomes Wholly Owned Subsidiary -- Acquisition Expands PHC Group’s Business Supporting Researchers and Healthcare Providers in Asia-Pacific --
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director and CEO: Shoji Miyazaki, hereafter PHCHD) announces that it has acquired the remaining 30% stake in
June 16, 15:00
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) (HUTCHMED) today announced that the European Medicines Agency (EMA) has validated and accepted for regulatory review
June 16, 14:16
Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million
Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million. This senior unsecured bond transactio
T cell (orange) interacting with cancer cell (blue) (Graphic: Business Wire)
June 15, 15:38
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies
With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare has today announced the first patient scanned in a Phase I clinical trial[2] of a first-of-its kin
June 14, 14:30
Sound Vaccine Secures KRW 180,000,000,000 Capital Commitment from GEM as Company Seeks to Get Uplisted on KOSDAQ
Sound Vaccine, Inc., (“Sound Vaccine”), a leading manufacturer of advanced hearing medical systems and patented hearing healthcare products, is pleased to announce that it has signed an agreement (“Ag
ZAP-X® Gyroscopic Radiosurgery® platform (Photo: Business Wire)
June 14, 10:40
ZAP Surgical Announces Upcoming Installation of Novel Non-Invasive Brain Tumor Treatment System in South Korea
ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Dankook University Hospital (DKUH) in Cheonan, South Korea, is slated to install the novel ZAP-X
June 13, 15:43
Thales Helps Lunit Accelerate the Growth of AI-based Software Cancer Diagnostic Solutions
Thales, a global leader in Software Monetization and Licensing, is collaborating with Lunit, a global provider of AI-powered cancer diagnostics and therapeutics solutions, to help accelerate the profi
June 13, 14:45
Community Health System Expands Use of Multiple Masimo Technologies, System-wide
Masimo (NASDAQ: MASI) and Community Health System (CHS), based in Fresno, California, today announced that CHS is adopting a variety of advanced Masimo monitoring technologies and solutions across its
June 09, 14:00
Lausanne University Hospital (CHUV) Anesthesiology Department Adopts Masimo W1™ for Use in Preoperative Patient Assessment
Masimo (NASDAQ: MASI) today announced that the Department of Anesthesiology at the Lausanne University Hospital (CHUV), one of Switzerland’s premier academic institutions, has chosen to make the Masim
June 09, 10:50
Parse Biosciences Launches CRISPR Detect
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unpreceden
June 08, 15:30
Chef Marcus Samuelsson Invests in Aleph Farms, Plans to Serve Aleph Cuts Cultivated Steaks
Aleph Farms, a cellular agriculture company designing new ways to grow quality animal products, today announced that Chef Marcus Samuelsson is joining the company as an investor, culinary advisor and
June 08, 14:30
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
Today, Organon (NYSE:OGN), a global healthcare company focused on women’s health, and CAF, Development Bank of Latin America, signed a memorandum of understanding (MOU) to contribute to the United Nat
June 08, 11:50
Kenvue to Announce Second Quarter 2023 Results on July 20, 2023
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its financial results for the second quarter ending July 2, 2023, will be re
June 08, 08:30
CORELINE SOFT Participates in ACTI 2023... Asian Medical AI Experts Invited as Speakers
SEOUL - Coreline Soft (CEO Jinkook Kim, Jungpill Choi), a company specializing in medical artificial intelligence (AI), participates in the ‘5th Asian Society of Thoracic Radiology & 22nd Korean Socie
25 per page50 per page75 per page100 per page